The delayed approval and price setting of Novartis Pharma’s Zolgensma (onasemnogene abeparvovec), a gene therapy for spinal muscular atrophy (SMA) listed in May, has raised questions about how the sakigake designation system should be operated. Despite being designated for the…
HOME > ACADEMIA
ACADEMIA
- Japanese Society of Hypertension to Verify Results of SPRINT Study
June 14, 2017
- AbbVie’s Novel Hep C Treatment Achieves 100% SVR in Genotype 1 Hepatitis C Patients with Compensated Cirrhosis
June 13, 2017
- DPP-4 Inhibitor Prevents Deterioration in Cardiac Diastolic Function in Diabetes Patients: Research Sub-Analysis
May 26, 2017
- Will Formularies Spread in Japan? Some Don’t Think So, but MOF Push Might Give Impetus
May 23, 2017
- “Authorized Biosimilars” Could Be Priced at 50% of Originators: Prof.
May 23, 2017
- JDS, JGS Publish 1st Guideline for Treatment of Diabetes in the Elderly
May 22, 2017
- PI/II Study Suggests Efficacy of Eisai’s Anti-Fractalkine Antibody for RA
April 25, 2017
- Gastric Cancer Guidelines Likely to Recommend Opdivo in 3rd Line Settings
April 24, 2017
- Hepatology Society to Release Updated Hep C Guidelines Soon, Reflecting Ximency Use
March 3, 2017
- NCC to Begin IIT for Pediatric ALL with Velcade Plus 5 Drugs
February 23, 2017
- AMED Drafts Japan’s First Manual for Treatment of Mitochondrial Diseases
February 20, 2017
- PCSK9 Inhibitors More Effective than Statins at Lowering LDL-C: New Atherosclerosis Prevention Guidelines
January 31, 2017
- Zonisamide Investigator-Led Trial for Dementia Symptoms to Begin in April
January 27, 2017
- OB-GYN Society Again Nudges Govt to Reinstate HPV Vaccine Recommendation
January 19, 2017
- Reinstate HPV Vaccine Recommendation ASAP: OB-GYN Society
December 28, 2016
- NIBIOHN Bioinformatics Specialist Hopeful About Use of AI in Building Drug Discovery Support System
December 19, 2016
- New Lung Cancer Guidelines to Give Keytruda Grade A Recommendation as First-Line Treatment
December 19, 2016
- Need for Resistance Testing a Factor in Selection of IFN-Free Therapies for Hep C: Hepatologist
November 22, 2016
- Draft Guidelines on Pneumonia Treatment Set Guides for Selecting Antibacterial Agents: Respiratory Society
November 7, 2016
- Cancer Society to Issue New Lung Cancer Treatment GL in December; Positioning of Anti-PD-1 Antibodies Will Be Focus of Interest
October 31, 2016
ページ
When Jiho surveyed drug makers on the non-sales criteria they use to evaluate reps’ performance, it received a variety of…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In a change striking to the very core of the traditional Japanese salaryman, “We are seeing the coronavirus ushering in a new way of working… and I think it’s about time,” says Ivan Tselichtchev, Professor of Economics at the Niigata…